DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer

BACKGROUND: Adjuvant chemotherapy (ACT) with 5-FU alone or 5-FU plus platinum after curative surgery improves the prognosis of pStage II-III gastric cancer (GC). However, only a subset of patients benefits from adjuvant platinum. To avoid the side effects of platinum, it is significant to accurately...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Zhiyuan, Yu, Beiqin, Pan, Tao, Li, Fangyuan, Li, Jianfang, Hou, Junyi, Liu, Wentao, Su, Liping, Zhu, Zhenggang, Yan, Chao, Liu, Bingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636483/
https://www.ncbi.nlm.nih.gov/pubmed/36332599
http://dx.doi.org/10.1016/j.tranon.2022.101577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636483/
https://www.ncbi.nlm.nih.gov/pubmed/36332599
http://dx.doi.org/10.1016/j.tranon.2022.101577

Ejemplares similares